Review

Circulating Biomarkers for the Prediction of Abdominal Aortic Aneurysm Growth

Petroula Nana 1,*, Konstantinos Dakis 1, Alexandros Brodis 2, Konstantinos Spanos 1 and George Kouvelos 1

1 Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Mezourlo, 41110 Larissa, Greece; kostasdakis1994@gmail.com (K.D.); spanos.kon@gmail.com (K.S.); geokouv@gmail.com (G.K.)
2 Department of Neurosurgery, Larissa University Hospital, Faculty of Medicine, School of Health Sciences, University of Thessaly, Mezourlo, 41110 Larissa, Greece; alexgbrodis@yahoo.com

* Correspondence: petr.nana7@hotmail.com; Tel.: +30-241-350-2154

Citation: Nana, P.; Dakis, K.; Brodis, A.; Spanos, K.; Kouvelos, G. Circulating Biomarkers for the Prediction of Abdominal Aortic Aneurysm Growth. J. Clin. Med. 2021, 10, 1718. https://doi.org/10.3390/jcm10081718

Abstract: Background: Abdominal aortic aneurysm represents a distinct group of vascular lesions, in terms of surveillance and treatment. Screening and follow-up of patients via duplex ultrasound has been well established and proposed by current guidelines. However, serum circulating biomarkers could earn a position in individualized patient surveillance, especially in cases of aggressive AAA growth rates. A systematic review was conducted to assess the correlation of AAA expansion rates with serum circulating biomarkers. Methods: A data search of English medical literature was conducted, using PubMed, EMBASE, and CENTRAL, until 7 March 2021, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement (PRISMA) guidelines. Studies reporting on humans, on abdominal aortic aneurysm growth rates and on serum circulating biomarkers were included. No statistical analysis was conducted. Results: A total of 25 studies with 4753 patients were included. Studies were divided in two broad categories: Those reporting on clinically applicable (8 studies) and those reporting on experimental (17 studies) biomarkers. Twenty-three out of 25 studies used duplex ultrasound (DUS) for following patients. Amongst clinically applicable biomarkers, D-dimers, LDL-C, HDL-C, TC, ApoB, and HbA1c were found to bear the most significant association with AAA growth rates. In terms of the experimental biomarkers, PIIINP, osteopontin, tPA, osteopontin, haptoglobin polymorphisms, insulin-like growth factor I, thioredoxin, neutrophil extracellular traps (NETs), and genetic factors, as polymorphisms and microRNAs were positively correlated with increased AAA expansion rates. Conclusion: In the presence of future robust data, specific serum biomarkers could potentially form the basis of an individualized surveillance strategy of patients presenting with increased AAA growth rates.

Keywords: abdominal aortic aneurysm; biomarkers; aneurysm growth

1. Introduction

Despite abdominal aortic aneurysm (AAA) being an asymptomatic entity, rupture complicates this silent pathology with a high mortality risk. Aneurysm identification on incidental imaging or screening programs at an early stage and small diameter allows for a close surveillance and repair [1]. However, not all aneurysms expand with the same rate and are not associated with the same risk of rupture, while diameter cannot always predict the physical evolution of an AAA [2–4]. A plethora of studies using imaging modalities and AAA anatomical characteristics tended to define models that could describe the expansion model of small or larger AAAs [5–8]. From ultrasonography to modern mathematical flow models, different methods have been used to identify these markers that could eliminate this group of patients needing closer re-evaluation and earlier management [9].

As different anatomical characteristics recorded on imaging modalities have been associated with aneurysm expansion, an analogous interest exists regarding the application of biomarkers that could identify AAA growth [10,11]. However, important discrepancies...
exist among the available studies [11]. A large spectrum of biomarkers is recorded in the current literature, from the commonly applied clinical circulating biomarkers to more specific sophisticated genetic models that could be used to evaluate AAA expansion rate [12]. The need to predict aneurysm evolution and if possible, to hamper sac expansion, is of high interest, as this approach would permit a closer surveillance screening and a more individualized therapeutic approach.

Along this line, a systematic review was conducted to present the existing evidence of different circulating biomarkers that may have a potential role on AAA growth prediction.

2. Materials and Methods

2.1. Eligible Studies

The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed [13]. Studies of English medical literature, reporting data on the evaluation of biomarkers (see Section 2.5), regarding their potential role on the identification of AAA growth (see Section 2.5) on humans, were considered eligible. Studies referring to data based on animal studies, any other aortic pathology besides AAA, and non-plasma circulating biomarkers (unavailable by venipuncture) were excluded. Scientific council approval in terms of ethical considerations was not required due to the nature of the study. Data extraction and methodological assessment was carried out by two independent investigators (P.N., K.D.). Any discrepancy was resolved after consultation by a senior investigator (G.K.). Consequently, a full-text review of the eligible studies was conducted, respecting the eligibility and exclusion criteria (Figure 1).

2.2. Search Strategy

A data search of English medical literature was conducted, the endpoint being 7 March 2021. The established medical databases PubMed, EMBASE, and CENTRAL were searched under the patient/population, intervention, comparison and outcomes (PICO) model, in order to determine the clinical questions and select the appropriate articles (Supplementary Table S1) [14]. The following search terms including Expanded Medical Subject Headings (MeSH) were used in various combinations: Abdominal aortic aneurysm, growth, biomarker. Primary selection was constructed on titles and abstracts, while a secondary investigation was executed based on full texts.

2.3. Data Extraction

A standard Microsoft Excel extraction file was developed. Extracted data included general data such as article author, year of publication, study period, journal of publication, and type of study. In addition, clinical data extracted from text or tables included the number of patients included, cohort characteristics, biomarker in evaluation, method of biomarker assessment, growth rate definition in each study, type of imaging used, correlation of biomarker to AAA growth, and statistical significance.

2.4. Quality Assessment

Quality assessment for individual studies and risk of bias evaluation was addressed using the ROBINS-I tool [15] for observational, non-randomized studies and the RoB-II tool [16] for randomized, controlled studies. Observational studies were judged as bearing a “Low”, “Moderate”, “Serious”, or “Critical” risk of bias, based on 7 domains, while RCTs were evaluated bearing a “Low”, “Some concerns”, or a “High” risk of bias, based on 5 domains (Supplementary Table S2). Risk of bias evaluation was carried out by two independent investigators (P.N., K.D.). In cases of disagreement, a third author was advised (G.K.).
Figure 1. The flow chart of the selection process according to PRISMA statement.

2.5. Definitions

A biomarker was considered a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention, as defined by the biomarkers.

2.6. Definitions Working Group

AAA growth was considered as the difference among two measurements of the maximal anteroposterior diameter of a diagnosed abdominal aortic aneurysm, based on measurements achieved either by ultrasonography (US), computed tomography (CT) or magnetic resonance imaging (MRI), between two set timepoints, at least 12 months apart or more. AAA growth was measured as mm/year [17].

2.7. Statistical Analysis

Only descriptive data were presented, because this systematic review did not aim to compare the efficacy of biomarkers on AAA growth.
3. Results

Twenty-five studies with 4753 patients were included in this systematic review. To facilitate data presentation, the studies were divided into two groups. The first group included studies assessing clinically applicable biomarkers and the second group included studies recording data on experimental biomarkers not used in the daily clinical practice.

Eight studies presenting data on clinical biomarkers were included; one randomized control trial [18], 3 prospective [19–21], and 4 retrospective [22–25] observational studies, published between 2008 and 2018 (Table 1). All analyses assessed patients that underwent screening controls or were hospital referrals and presented an AAA of more than 30 mm of diameter (range 30–50 mm). Considering experimental circulating biomarkers, 17 articles were included, all presenting results from prospective [26–41] observational studies, except one retrospective [42] analysis (Table 2). In total, 3152 patients with AAA of more than 30 mm were included (range 30–49 mm).

| Author            | Year of Publication | Journal                                                                 | Type of Study                      | Number of Patients | Study Cohort                                                                 |
|-------------------|---------------------|-------------------------------------------------------------------------|------------------------------------|--------------------|-----------------------------------------------------------------------------|
| Ceniga et al.     | 2009                | European Journal of Vascular and Endovascular Surgery                  | Prospective observational (case-control) | 70                 | 35 patients (AAA 30–49 mm)—35 healthy controls (AAA < 30 mm)               |
| Colledge et al.   | 2011                | European Heart Journal                                                  | Prospective observational (case-control) | 299                | 299 patients (AAA 30–40 mm) (261; AAA 30–39 mm—38; AAA 40–49 mm)           |
| Ceniga et al.     | 2014                | Annals of Vascular Surgery                                              | Prospective observational (case series) | 96                 | 96 patients (AAA 30–49 mm)                                                 |
| Burillo et al.    | 2015                | Thrombosis and Hemostasis                                               | Retrospective observational (case-control) | 122                | 122 patients (AAA > 30 mm) (86; AAA 30–49 mm—36; AAA > 50 mm)              |
| Moxon et al.      | 2016                | Atherosclerosis                                                        | Retrospective observational (case-control) | 250                | 250 Patients (AAA 30–39 mm) (65; AAA with iron overload (Ferritin > 200 ng/mL)—185 without IO) |
| Kristensen et al. | 2017                | Arteriosclerosis, Thrombosis, and Vascular Biology                     | Retrospective observational (case-control) | 319                | 319 patients (AAA 30–49 mm) (61 AAA with DM—258 without DM)                |
| Deeg et al.       | 2016                | Current Medical Research and Opinion                                     | Randomized controlled trial (RCT)   | 93                 | 93 patients (AAA 35–50 mm) (44 AAA with doxycycline—49 AAA without doxycycline) |
| Sundermann et al. | 2018                | Blood Advances                                                         | Retrospective observational (case-control) | 352                | 169 patients (AAA > 25 mm) (84 slow growing AAA, <2 mm/year; 85 fast growing AAA, >2 mm/year)—68 subaneurysmal aorta (25–29 mm)—115 healthy control (AA < 25 mm) |

All analyses assessed patients that underwent screening controls or were hospital referrals and presented an AAA of more than 30 mm of diameter. Notes: AAA: abdominal aortic aneurysm; DM: diabetes mellitus.
Table 2. General characteristics of studies on circulating experimental biomarkers.

| Author               | Year of Publication | Journal                                      | Type of Study                      | Number of Patients | Study Cohort                                                                 |
|----------------------|---------------------|----------------------------------------------|------------------------------------|--------------------|-------------------------------------------------------------------------------|
| Satta et al. [26]    | 1997                | Journal of Vascular Surgery                  | Prospective observational (case-control) | 139                | 139 patients with AAA under surveillance and or hospital referrals (AAA > 40 mm) |
| Lindholt et al. [27] | 2003                | European Journal of Vascular & Endovascular Surgery | Prospective observational (case series) | 70                 | 70 patients from the Viborg cohort (screening program) (AAA 30–49 mm)         |
| Colledge et al. [28] | 2007                | Arteriosclerosis, Thrombosis and Vascular Biology | Prospective observational (case-control) | 198                | 146 patients from the Western Australia Screening Study and 52 referrals from a tertiary hospital (AAA > 30 mm) |
| Flondell–Site et al. [29] | 2010            | Vascular and Endovascular Surgery           | Prospective observational (case series) | 397                | 178 patients with AAA, referrals at the Malmo Hospital and 219 control healthy individuals |
| Wiernicki et al. [30] | 2010               | Journal of Vascular Surgery                  | Prospective observational (case series) | 83                 | 83 patients with AAA under surveillance (AAA diameter, non-applicable)         |
| Martinez–Pinna et al. [31] | 2010          | Atherosclerosis (TRX)                        | Prospective observational (case series) | 166                | 88 patients from a Spanish screening cohort and 78 patients from the Viborg cohort (screening program) (AAA > 30 mm) |
| Martin–Ventura et al. [32] | 2011          | Atherosclerosis (sTWEAK)                     | Prospective observational (case series) | 150                | 43 patients with AAA vs. 28 healthy controls and 79 patients from the Viborg cohort (AAA 30–49 mm) |
| Lindholt et al. [33] | 2011                | European Journal of Vascular & Endovascular Surgery (IGF) | Prospective observational (case series) | 115                | 115 patients with AAA from a screening program (AAA > 30 mm)                   |
| Ramos–Mozo et al. [34] | 2012         | Atherosclerosis (NGAL)                      | Prospective observational (case series) | 100                | 100 patients with AAA under surveillance from a screening program (AAA median diameter 37.5 mm) |
| Ye et al. [35]       | 2016                | Atherosclerosis(SNPs)                       | Prospective observational (case series) | 651                | 651 patients participants in the Mayo Clinic Vascular Disease Biorepository, with AAA with at 2 least to diameter measurements on surveillance program (AAA > 30 mm or with a history of open or endovascular AAA repair) |
| Wainhanen et al. [36] | 2017            | Atherosclerosis                             | Prospective observational (case-control) | 242                | 192 patients with AAA and 50 healthy controls from a screening program and hospital referral (AAA > 30 mm) |
| Wang et al. [37]     | 2018                | European Journal of Vascular & Endovascular Surgery | Prospective observational (case-control) | 749                | 551 male patients with AAA and 198 age-matched healthy controls from the Viborg cohort (screening program) (AAA > 30 mm) |
| Ahmad et al. [38]    | 2018                | European Journal of Vascular & Endovascular Surgery | Prospective observational (case series) | 97                 | 97 patients—NHS referrals under surveillance for AAA (mean diameter 39 mm) |
Among studies presenting clinical biomarkers, the most commonly applied one was D-dimers which was assessed in three studies [20,21,25]. D-dimers’ role as an indicator of the process of thrombosis and thrombolysis and their known association with other cardiovascular entities has been assessed to further identify their potential impact on AAA evolution. The lipidemic biomarkers (total cholesterol [18], apolipoprotein-B [18], low density lipids (LDL) [18] and high-density lipids (HDL) [22]) and C-reactive protein (CRP) [19] have been used due to their proven role on the process of atherothrombosis and their relationship to a higher-risk of cardiovascular events. In one study, the role of HbA1c was addressed due to the already known negative association between diabetes and AAA pathogenesis [24].

All the markers assessed in the studies, as well as the potential underlying etiopathologic relationship between them and AAA evolution is presented in Table 3. In the experimental group, a variety of biomarkers was applied to identify prediction models in AAA evolution (Table 4). Nine out of them participate in the inflammation cascade while 3 are associated with the physiological coagulation mechanisms and 2 on the degenerative procedures of the tissues. Neutrophil gelatinase-associated lipocalin was studied as an indicator of the inflammatory degenerative process of aneurysm formation [34,42] and evolution while the potential role of insulin-like growth factor I (IGF-I) and II was analyzed under the spectrum of the negative association between diabetes and AAA [33]. The etiopathological association of all experimental markers and AAA growth is also presented in Table 4.

For the evaluation of aneurysm growth, duplex ultrasonography (DUS) was used in the vast majority of the studies (23 out of 25 studies) [18–28,30–40,42]. Aneurysm growth definition varied among studies. The change in the antero-posterior diameter of the aneurysm sac during the whole observation period divided by the aforementioned time interval (diameter at the latest evaluation-diameter at the initial evaluation/time interval in years) was used in 15 studies to identify the annual growth rate of the aneurysm. All approaches used to evaluate AAA growth rate are presented in Tables 3 and 4.
Table 3. Specific characteristics of studies on circulating clinical biomarkers.

| Author            | Aim                                                                 | Etiology                                                                 | Biomarker | Method                              | Growth Rate                        | Type of Imaging                   |
|-------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|-----------|-------------------------------------|------------------------------------|-----------------------------------|
| Ceniga et al. [19]| Identification of possible association of CRP, Lpa, Lpa with AAA growth | CRP, independent risk factor for atherosclerosis, CVD, symptomatic/ruptured AAA, Lpa; conflicting data on CVD, Lpa; established role in CVD, CHD, atherothrombosis, stroke | CRP, Lpa  | CRP, Lpa; immunoturbidimetric method, Lpa; immunonephelometric method | Millimeter difference of maximum transverse and anteroposterior external diameters of the infrarenal aorta, perpendicular to the aortic axis, in ultrasound/CT scans taken 12 months apart (mm/year); (FUP: 1 year) | DUS (AAA 30–39 mm), CT (AAA 40–49 mm) |
| Colledge et al. [20]| Identification of possible association of D-dimers, CRP, creatinine in AAA growth rate | D-dimers; indicator of thrombosis-thrombolysis (DVT, CVD, AAA) | D-dimers  | D-dimers: ELISA or latex-enhanced immunoassay | Millimeter difference of the infrarenal aorta in ultrasound scans every 6 or 12 months (mm/year). (Median FUP: 5.5 years) | DUS |
| Ceniga et al. [21]| Identification of possible association of various biomarkers in AAA growth rate | D-dimers; indicator of thrombosis-thrombolysis (DVT, CVD, AAA), cystatin-C; Recent biomarker of CVD (MCI, stroke, HF, PAD, PAP complex; possible role in atherosclerosis | D-dimers, | D-dimers; ELISA, cystatin-C; N latex cystatin-C assay; PAP complex, ELISA | Millimeter difference of measured maximum outer-to-inner transverse, anteroposterior, and lateral aortic diameters, perpendicular to the aortic axis, in US/CT scans taken 12 months apart (mm/year); (FUP: 1 year) | DUS (AAA 30–39 mm), CT (AAA 40–49 mm) |
| Burillo et al. [22]| Identification of possible association of HDL-C to AAA growth | HDL-C; inversely associated with CVD, atheromatosis, atherothrombosis | HDL-C     | ELISA                              | Millimeter difference of measured maximal perpendicular anteroposterior diameter, in US/CT scans taken 12 months apart (mm/year); mean FUP: 8.1 years | DUS (AAA 30–50 mm), CT (AAA > 50 mm) |
| Moson et al. [23]| Identification of possible association between ferritin and AAA diagnosis, size, growth | Ferritin; marker of CVD, iron deposition in histologic examination of AAA | Ferritin   | ELISA                              | Yearly AAA growth rate was calculated as a percentage of the size of the AAA in the preceding year (e.g., AAA growth rate between screening and year 1 rescan = 100 × (year 1 AAA diameter/AAA diameter at screening)−1) | DUS |
| Kristensen, et al. [24]| Identification of possible association of HbA1c to AAA growth | HbA1c; risk factor for atherosclerosis, CVD—possible protective factor in AAA pathogenesis | HbA1c     | Not stated                         | Millimeter difference in maximal anterior-posterior AAA diameter in US scans taken 12 months apart (mm/year); mean FUP: 3.88 years | DUS |
| Deeg et al. [18]| Identification of possible association of various biomarkers in AAA growth rate between AAA patients receiving and not receiving doxycycline | TC, LDL, biglycan; atherosclerosis and CVD association, elastin products, degradation products associated with AAA pathogenesis | Total cholesterol, ApoB, elastin DP, biglycan DP, cathepsin S, LDL | Multi-analyte profiling technology | Millimeter difference of measured maximal anteroposterior AAA diameter, perpendicular to the blood flow, from inner-to-inner wall, in US scans taken 6–12–18 months apart (mm/month); FUP: 18 months | DUS |
| Sundermann et al. [25]| Identification of possible association of D-dimmers, TAT, PF4 with AAA stratification and growth | D-dimmers; indicator of thrombosis-thrombolysis (DVT, CVD, AAA), TAT, increased levels in CD, stroke, PAD, atherothrombosis, PF4; inflammatory/coagulative role in AAA thrombus | D-dimers, TAT complex, PF4 | ELISA                | Millimeter difference of measured maximum AAA diameter, in US scans taken 12 months apart (mm/year); slow-growing: < 2 mm/year; fast-growing: > 2 mm/year | DUS |

All the markers assessed in the studies, as well as the potential underlying etiopathologic relationship between them and AAA evolution, are presented. Notes: AAA: Abdominal aortic aneurysm; CD: Coronary disease; CHD: Cardiac heart failure; CT: Computed tomography; CVD: Cardiovascular disease; DVT: Deep vein thrombosis; HF: Heart failure; MI: Myocardial infarction; FUP: Follow-up; PAD: Peripheral arterial disease; US: Ultrasonography.
Table 4. Specific characteristics of studies on circulating experimental biomarkers.

| Author               | Aim                                                                 | Etiology                                                                 | Biomarker        | Method                        | Growth Rate Definition | Imaging |
|----------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|------------------|-------------------------------|------------------------|---------|
| Satta et al. [26]    | Identification of the association between serial changes in the concentration of the aminoterminal propeptide of type III procollagen (PIIINP) in serum to the rate of AAA growth | PIIINP; synthesis of type III collagen; increased turnover of in patients with AAAs when compared with patients with atherosclerotic aorto-iliac occlusive disease | Serum PIIINP | Equilibrium-type radioimmunoassays | No definition recorded in text (FUP:NA) | DUS     |
| Lindholt et al. [27] | Identification of the activating pathways of plasminogen as predictors of AAA progression | tPA, IgA and CP and S-cotinine; markers of fibrinolytic function in plasma and activation of the degenerative processes in tissues-proteolysis; plasmin and antiplasmin complex (PAP) correlates with aneurysmal expansion and prediction for cases expanding to operation recommendable sizes | tPA, IgA ± CP, and S-cotinine | ELISA | Change in anterior-posterior diameter divided by years in annual units (FUP: 3.5 years) | DUS     |
| Colledge et al. [28] | Identification of the relationship between serum osteopontin (OPN) concentrations, polymorphisms of the OPN gene, and AAA presence and growth in humans | OPN: Bone remodeling, vascular calcification, and tumor metastasis; inflammation, proteolysis, and atherosclerosis, integral processes in AAA and animal models | OPN (osteopontin) | ELISA | Maximum transverse and anteroposterior diameter measurements (FUP: 3 years) | DUS     |
| Flondell–Site et al. [29] | Quantification plasma metalloproteinases (MMP)-2 and –9 and their endo-genous tissue inhibitors (TIMP-1, serpine-1, tPa-serpine-1, and the APC-PCI complex) in patients with AAA and their relationship between these markers and AAA diameter and growth | APC-PCI; physiological inhibitors of free tissue plasminogen activator (tPA) with proteolytic and fibrinolytic activity; increased concentrations of the APC-PCI complex in patients with AAA and imbalances between MMPs and their inhibitors have been reported to occur in AAA | APC-PCI (activating C protein–protein C inhibitor), MMP-2, MMP-9, and their endogenous tissue inhibitors, TIMP-1, serpine-1, tPa-serpine-1 | Biotrak activity assay systems, ELISA, DELFIA | Change in anterior-posterior diameter during the whole observation divided by years in annual units (FUP: 7 years) | NA      |
| Wiernicki et al. [30] | Identification of the association between haptoglobin polymorphism (Hp) phenotype to AAA growth rate and assessment of serum elastase activity and markers of inflammation in patients with newly diagnosed AAA | Hp gene; hemoglobin-binding protein expressed by a genetic polymorphism as three major phenotypes: Hp 1-1, Hp 2-1, and Hp 2-2; suppression of inflammatory responses; influences the dilatation of the abdominal aorta and probably has a direct effect on the degradation of elastin in the atherosclerotic aorta | HP (haptoglobin polymorphism) | Starch-gel electrophoresis | Growth rate identified as mm/y = max diameter at last scan – max diameter at first scan/time interval (FUP:NA) | DUS     |
| Author                  | Aim                                                                 | Etiology                                                                 | Biomarker                      | Method                      | Growth Rate Definition                                                                 | Imaging |
|-------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------|-----------------------------|----------------------------------------------------------------------------------------|---------|
| Martinez–Pinna et al.   | Identification of thiorexodin (TRX) in conditioned media from the different layers of AAA thrombus, and in serum of patients with AAA | TRX; reactive oxygen species in inflammation and hemolysis in luminal layer of the thrombus; intracellular antioxidant enzyme elevated in CAD and intraplaque hemorrhage | Thioredoxin (TRX)             | ELISA                       | Change in anterior-posterior diameter during the whole observation divided by years in annual units (FUP: NA) | DUS     |
| Martin–Ventura et al.   | Identification of the soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) with AAA growth rate | sTWEAK; cellular growth, proliferation, migration, osteoclastogenesis, angiogenesis, apoptosis; marker of CVD, CAD, carotid stenosis, and PAD that may have an association to AAA | sTWEAK (soluble tumor necrosis factor-like weak inducer of apoptosis) | ELISA                       | Change in anterior-posterior diameter during the whole observation divided by years in annual units (FUP: 5 years) | DUS     |
| Lindholt et al.         | Estimation of the potential role of insulin-like growth factor 1 (IGF-1) and IGF-2 as biomarkers for AAA | IGF-1; mediator of CVD; vascular protective factor in AAA | Insulin-like growth factor 1 (IGF-1) and 2 (IGF-2) | Validated, in-house time-resolved immunofluorometric assays | Change in anterior-posterior diameter during the whole observation divided by years in annual units (FUP: 10 years) | DUS     |
| Ramos–Mozo et al.       | Identification of the relationship of NGAL concentrations in the plasma of three groups of patients and related them to the presence, size and growth of AAAs | Plasma NGAL; neutrophil-derived protein during inflammation; marker of CV risk factors in asymptomatic atherosclerosis | NGAL (neutrophil gelatinase-associated lipocalin) | ELISA                       | NA                                                                                       | DUS     |
| Ye et al.               | Association of multi-locus generic risk score (GRS) based on single nucleotide polymorphisms (SNPs) associated with AAA in genome-wide association studies (GWAS) with AAA growth prediction beyond conventional risk factors | Genome-wide association studies (GWAS); several common single nucleotide polymorphisms (SNPs); known association with AAA presence | Multi-locus GRS | Illumina Infinium Human core Exome Array, and Illumina Human 610 and 660 W Quad-v1 | Latest assessed diameter (mm)/pre-operation minus first diameter (mm)/time interval (years) (FUP: NA) | DUS, CT, MRI, DSA |
| Wainhanen et al.        | Associations between a wide range of micro-RNAs (miRNAs) and presence and growth of AAA | Circulating miR; 8–22 nucleotide short non-coding RNAs secreted by cells that regulate expression of target genes by interfering with transcription or inhibiting translation; associated with AAA presence (miR-155, miR-191-3p, miR-455-3p, miR-1281, and miR-411) | microRNA (miRNA) | miRCURYTM RNA isolation kit-biofluids/PCR | NA (FUP: NA)                                                                            | DUS     |
| Author                  | Aim                                                                 | Etiology                                                                 | Biomarker              | Method          | Growth Rate Definition                                                                 | Imaging |
|------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------|-----------------|----------------------------------------------------------------------------------------|---------|
| Wang et al. [37]       | Association of plasma cystatin B with AAA presence, size, growth rate, or need for later surgical repair | Cystatin B; marker of human malignant tumors in lipopolysaccharide (LPS) activated human blood monocytes and in interferon-g induced mouse macrophages, cystatin B deficiency in mice or loss of function mutation in humans associated with neurological dysfunction; aortic wall weakening process is mediated by proteases, including cysteinyll cathepsins, negative correlation of human plasma cystatin C levels with AAA size and annual expansion rate | Cystatin B             | ELISA           | Change in anterior-posterior diameter during the whole observation divided by years in annual units (FUP: 5 years) | DUS     |
| Ahmad et al. [38]      | Investigation of the relationship between serum interleukin (IL-1α) levels and asymptomatic infrarenal AAA growth rates, absolute size, and morphology | II-1α; pro-inflammatory cytokine not normally detectable in the circulation in health individuals; non-specific CVD marker; marker of aortic disease related to AAA diameter | IL-1α                  | Boster immunoassay kit              | Absolute (mm) change in maximum AP diameter and absolute (mm/year) change in maximum AP diameter over time (FUP:NA) | DUS     |
| Groeneveld et al. [42] | Investigation of the role of neutrophil gelatinase-associated lipocalin (NGAL) in AAA development and rupture | NGAL; acute phase protein stored in neutrophils, diagnostic and prognostic tool for several CVD; potential prevention of metalloproteinase (MMP-9) from inactivation and aortic wall degeneration; NGAL inhibition in mice attenuation of AAA growth, protective role against apoptosis | NGAL (neutrophil gelatinase-associated lipocalin) | ELISA           | NA (multiple measurements to assess the expansion rate, FUP: NA)                      | CT or DUS |
| Lindholt et al. [39]   | Investigation of the potential role of plasma microfibrillar-associated protein 4 (pMFAP4) as a biomarker of AAA | MFAP4; factor expressed in human elastic fibers in blood vessels, induction of smooth muscle cell proliferation and migration and monocyte chemotaxis; marker of tissue remodeling-related diseases | Microfibrillar-associated protein 4 (MFAP4) | AlphaLIISA       | Change in anterior-posterior diameter during the whole observation divided by years in annual units (FUP: 5 years) | DUS     |
| Memon et al. [40]      | Identification of diagnostic and prognostic biomarkers for AAA diameter and growth | MPO, tissue-type plasminogen activator (t-PA), CSTB; proteolytic and fibrinolytic activity; pathophysiologic marker of CVDs | Myeloperoxidase (MPO), tissue-type plasminogen activator (t-PA), and cystatin-B (CSTB) | Proseek Multiplex CVD III96 × 96 panel | NA | DUS |
Table 4. Cont.

| Author            | Aim                                                                 | Etiology                                                                 | Biomarker                      | Method    | Growth Rate Definition | Imaging |
|-------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------|-----------|------------------------|---------|
| Eilenberg et al. [41] | Identification of the diagnostic or prognostic role of neutrophil extracellular traps (NETs) in AAA patients | NETs; marker of excessive neutrophil activation in destruction of pathogens; marker of AAA development in a mouse model by propagating the local immune reaction in aneurysm tissue | Neutrophil extracellular traps (NETs) | ELISA     | The AAA maximum diameter is measured with semi-automatic tools with mean intra- and interobserver variability ranging at 0.13 and 0.27 mm, respectively | CTA     |

D-dimers were positively associated in 3 studies with aneurysm growth with an associated statistical significance. In accordance, the lipidemic markers played a predictive role in AAA expansion; total cholesterol and apolipoprotein-B had a positive relation while HDL presented a negative association; higher HDL levels were associated with lower AAA growth. The negative association of diabetes and AAA pathogenesis was detected by the negative correlation between HbA1 and expansion rate. The association between clinical biomarkers and AAA growth is presented in Table 5. Among the experimental biomarkers, amino-terminal propeptide of type III procollagen (PIIINP) [26], tissue-type plasminogen activator (tPA) [27,29,40], osteopontin [34], haptoglobin polymorphism [30], IGF I and II [33], thioredoxin (TRX) [31], neutrophil extracellular traps (NETs) [41], and genetic factors, as polymorphisms [35] and micro RNAs [36] were positively associated with aneurysm expansion. Two studies reported no association between NGAL and AAA growth [34,42]. All data regarding the experimental markers are available in Table 6.

Table 5. The association between clinical biomarkers and AAA growth. Notes: AAA: Abdominal aortic aneurysm.

| Author          | Association of Biomarker to Growth | Significance | Additional Information |
|-----------------|-----------------------------------|--------------|------------------------|
| Ceniga et al. [19] | A1at; positive correlation with AAA growth | $r = 0.55, p = 0.004$ | CRP; no association, Lp(a); no association |
| Colledge et al. [20] | D-dimers; positive correlation with AAA growth: DD > 150 ng/mL-AG: 0.7 mm/DD~150–300 ng AG: 0.8/DD~300–900 ng/mL-AG: 1.3 mm/DD > 900 ng/mL-AG: 1.7 mm, $p < 0.001$ | $r = 0.39, p < 0.001$ | Multiple linear regression analysis revealed significant positive associations of rank-transformed D-dimer (beta = 0.29, $p = 0.001$) with AAA growth |
| Ceniga et al. [21] | D-dimers; 1 ng/mL increase Growth 0.0062 mm/year b = 0.0062, $\beta = 0.38$ (95% CI 0.001–1.011) Adjusted R2 = 0.2) cystatin-C; OR = 10.04 (CI 95% 1.18–85.73), PAP; OR = 1.004 (CI 95% 0.999–1.01) | D-dimers; $p < 0.1$/Cystatin-C; $p < 0.05$, PAP; $p < 0.2$ | Continuous variable: Growth rate mm/year/dichotomous variable: Stability = <2 mm/year, expansion = >2 mm/year |
| Burillo et al. [22] | HDL-C; higher HDL-C Levels associated with lower AAA growth rate | $r = -0.18, p = 0.07$ | |
| Moxon et al. [23] | No association | NS | |
| Kristensen et al. [24] | HbA1c; negative correlation with AAA growth: 1.8 mm/year (CI, 0.99–2.65; $p < 0.000$) less in HbA1c 44–77 mmol/mol vs. 28–39 mmol/mol | $r = -0.177; p = 0.002$ | |
### Table 5. Cont.

| Author                  | Association of Biomarker to Growth                                                                 | Significance | Additional Information |
|-------------------------|---------------------------------------------------------------------------------------------------|--------------|------------------------|
| Deeg et al. [18]        | Without DXC: TC, ApoB; positive correlation with AAA growth/with DXC: EP; positive correlation with AAA growth | r1 = 0.38, unadjusted  
  p1 = 0.011, r2 = 0.41, unadjusted  
  p2 = 0.005, r3 = 0.33, unadjusted  
  p3 = 0.031          |              |
| Sundermann et al. [25]  | D-dimers; b = 0.21 mm/year increase per 500 ng increase; (CI 95% 0.09–0.33)/TAT;  
  b = 0.24 mm/year increase per 1µg/mL (95% CI 0.19–0.29)/fast/slow vs. Controls for D-dimers > 500 ng  
  OR = 7.19 (2.9–17.83)/6.23 (2.72–14.27), fast vs. slow for TAT > 4.2 µg/mL:  
  OR 5.37 vs. 240.02          | Continuous; p < 0.05, fast–slow; p < 0.001          | PF4; no association |

**AG**: Aneurysm growth; **DD**: D-dimers; **EP**: Elastin products; **TAT**: Thrombin-antithrombin complex.

### Table 6. The association between experimental biomarkers and AAA growth.

| Author                  | Association of Biomarker to Growth                                                                 | Significance | Additional Information |
|-------------------------|---------------------------------------------------------------------------------------------------|--------------|------------------------|
| Satta et al. [26]       | Acceleration of AAA growth increased s-PIIINP correlation in the course of AAA disease (from 0.22–0.55) | p = 0.002 (p = 0.01 during the first year) | The correlation between thrombus changes and s-PIIINP tends to be lower than between diameter and s-PIIINP, except in the first year (p = 0.02 at the end of follow-up) |
| Lindholt et al. [27]    | Positive correlation between annual expansion rate and tPA, IgA ± CP, and S-cotinine               | r = 0.37- p = 0.002,  
  r = 0.29- p = 0.006 and  
  r = 0.24- p = 0.038, respectively          | In multiple linear regression analyses adjusting for S-Cotinine, the correlation between tPA and expansion rate remained significantly correlated |
| Colledge et al. [28]    | Serum OPN correlated with aortic diameter change                                                  | p < 0.001    | Adjustment for other known risk factors for aortic expansion, serum OPN predicted AAA growth (p < 0.001) |
| Flondell–Site et al. [29]| No significant correlations between levels of MMP-2 or -9, TIMP-1, serpine-1, tPA- serpine-1, or the APC-PCI complex and yearly AAA growth, TIMP-1 levels independent predictors of fatal AAA rupture | NS, only for TIMP-1;  
  p = 0.036          | |
| Wiernicki et al. [30]   | Hp 2-1 patients associated with significantly higher growth rate (3.69 [2.40] mm/y) of AAA compared with patients with Hp 2-2 (1.24 [0.79], p < 0.00001) and Hp 1-1 (1.45 [0.68], p < 0.00004) | p = 0.00001, p = 0.00004          | Hp 2-1 associated with higher serum elastase activity and CRP concentration, Hp 2-1 phenotype only independent predictor of a higher AAA growth rate in multivariate analysis |
| Martinez–Pinna et al. [31]| Spearman’s correlation coefficient between TRX and AAA-growth rate. TRX predictive of patients expanding > 2 mm/year (area under ROC curve = 0.67, 95% CI, 0.55–0.79,  
  p = 0.01).          | p = 0.03          | TRX optimal cutpoint of 30 ng/mL associated with a 62% sensitivity and specificity |
| Author                  | Association of Biomarker to Growth                                                                 | Significance               | Additional Information                                                                 |
|------------------------|----------------------------------------------------------------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------------|
| Martin–Ventura et al.  | sTWEAK predictive for >2 mm/y growth rate (area under ROC curve = 0.71; 95% CI, 0.58–0.83); increase of 100 pg/mL of sTWEAK reduced risk of annual expansion rate above 2 mm by 38% (95% CI: 0.41–0.93) | $p = 0.003$ and $p = 0.021$, respectively | Inverse correlation between sTWEAK and AAA expansion rate ($r = -0.263; p = 0.031$) |
| Lindholt et al. [33]    | Positive correlation between plasma NGAL and retrospective AAA growth ($\rho = 0.4$, $p = 0.01$), significant after adjusting for other risk factors. NGAL plasma concentration weakly associated with averaged yearly AAA growth | $p = 0.01$ and $p = 0.2$, respectively |                                                                                       |
| Ramos–Mozo et al. [34]  | Serum IGF-I correlated positively with growth rate adjustment for potential confounders                     | $p = 0.004$               | The adjusted growth rate increased by 0.53 + 0.23 mm annually between the IGF-1 tertiles ($p = 0.013$). Serum IGF-I level predicted cases needing later surgery (AOC: 0.63; 95% CI), no association of IGF-II and AAA growth |
| Ye et al. [35]          | GRS (dichotomized by median), baseline size, diabetes, and family history associated with aneurysm growth rate (all, $p < 0.05$). Mean aneurysm growth rate 0.50 mm/year higher in those with GRS > median (5.78) than those with GRS median ($p = 0.01$), after adjustment for baseline size ($p < 0.001$), diabetes ($p = 0.046$), and family history of aortic aneurysm ($p = 0.02$) | $p = 0.01$               | Diabetes and current smoker, together with miR-335-5p and miR-125a-5p, with AUC of 0.84 with a specificity of 70% and sensitivity of 80% |
| Wainhanen et al. [36]   | 20 miRs differentially expressed between slow- and fast-growing AAAs (AUC 0.60–0.65)                      | $p < 0.005$               |                                                                                       |
| Wang et al. [37]        | In Pearson’s correlation test, plasma cystatin B not associated with AAA growth rate                          | $p = 0.1$                |                                                                                       |
| Ahmad et al. [38]       | No statistically significant relationship was detected between IL-1a and absolute AAA increase in maximum AP diameter ($\rho 1/4 0.127, p 1/4 0.214$) or absolute growth rate (mm/year) ($\rho 1/4 0.123, p 1/4 0.230$) | NS                       |                                                                                       |
| Groeneveld et al. [42]  | AAA expansion rate not correlated with NGAL blood plasma (or tissue)                                        | $p = 0.34$               |                                                                                       |
| Lindholt et al. [39]    | pMFAP4 significantly inversely associated with annual aneurysmal growth rate                                 | $p = 0.0074$             | No association of level of pMFAP4 in multivariate analysis                             |
Table 6. Cont.

| Author                     | Association of Biomarker to Growth                                                                 | Significance           | Additional Information                                                                 |
|----------------------------|---------------------------------------------------------------------------------------------------|------------------------|----------------------------------------------------------------------------------------|
| Memon et al. [40]          | MPO, tissue-type plasminogen activator (t-PA) and CSTB levels significantly associated with AAA growth | \( p = 0.013, 0.016, \) and 0.007, respectively | MPO best prognostic value in terms of AUC (AUC, 0.71; 95% CI 0.61–0.81, with a sensitivity of 80% and specificity of 59%, higher levels of MPO (\( \geq \)median) were associated with significantly faster growth of AAA median (IQR): 2.3 (2.9) mm/year) compared with lower MPO levels (median (IQR): 1.2 (1.1) mm/year) |
| Eilenberg et al. [41]      | Prognostic value of citH3 ranged at AUROC = 0.707 (\( p = 0.015 \)) citH3 superior to D-dimers (AUROC = 0.613, \( p = 0.186 \)) | \( p = 0.015 \)       | 194 ng/mL cut-off level for plasma citH3 to predict rapid progression (>2 mm/6 months) with 77% sensitivity und 64% specificity |

AAA: Abdominal aortic aneurysm.

Risk of Bias Evaluation

Twenty-four observational studies were assessed on 7 domains (ROBINS-I tool), while 1 RCT was assessed on 5 domains (RoB-II tool). Twenty-one [19–23,25,27–41] out of 24 observational studies were attributed a “Moderate” risk of bias, while the rest 3 [24,26,42] were attributed a “Serious” risk of bias (Supplementary Table S2). The RCT [18] was attributed a “Some Concerns” risk of bias grade. Confounders on which the studies were judged included consistency and control of method of biomarker evaluation, potential subgroup analysis of patients, method of imaging technique, and number and experience of imaging techniques operators.

4. Discussion

AAA represent a category of vascular lesions with high morbidity and mortality, especially in the case of aneurysm rupture. Current guidelines suggest elective repair based mainly on aneurysmal diameter and/or other characteristics of the AAA [8,43]. Proposed screening strategies vastly stand on imaging techniques, including mainly DUS, adhering to the phenomenon of increased rupture risk in patients of specific demographic attributes and AAA diameter [44]. Studies have shown that patients with particular aneurysmal attributes would be acceptable surgical candidates, especially for endovascular interventions, even if AAA diameter has not achieved the diameter’s threshold [45,46]. While AAA growth is observed through typical, time-set imaging follow-up, stratification of high-risk patients with expeditious AAA growth, through serum biomarkers, could be a valid approach for individualized imaging surveillance. These patients could benefit from a rather targeted surveillance approach as well as an early endovascular or open surgical repair.

The pathogenesis of AAAs advocates for an extensive list of serum circulating or histologically detected biomarker candidates. Each category bears an important role in the different phases of the natural history of AAA [47–49]. Biomarkers detected through histological evaluation of an AAA open surgical repair specimen do not conform with the concept of preoperative surveillance and disease progression and therefore cannot be used in clinical practice. However, serum circulating biomarkers appertaining to recognized pathophysiologic processes of AAA pathogenesis, including thrombosis, inflammation, extracellular matrix (ECM) degradation, lipid metabolism, as well as genetic predisposition, could potentially form the basis of a stratification screening or surveillance strategy for patients in need of more frequent follow-up.
As proposed by many studies, certain mediators or by-products of thrombosis and lipid metabolism have been linked to AAA growth. These biomarkers can be easily and cost-effectively implemented in everyday clinical practice [18–20,22,25]. D-dimers, a known fibrin degradation by-product, has been shown to be associated with AAA expansion, as higher levels have been correlated with increased growth rate. Correlation of other thrombosis-related biomarkers, including PAP complex [21,50], homocysteine [51], and TAT [25], has also been reported. Higher levels of HDL-C, a biomarker related to lipid metabolism, have been correlated with decreased AAA growth rates in a screening population [22]. Furthermore, increased levels of total cholesterol and apolipoprotein B, both markers easily quantified and major constituents of lipid metabolism, have been associated with increased growth rates of AAA [18]. On the other hand, given the potentially protective nature of diabetes mellitus in AAA, glycated hemoglobin (HbA1c) has been studied as a possible biomarker of inverse association with AAA expansion [52–55]. A lower growth rate was observed in patients with higher HbA1c levels; 1.8 mm/year decrease of rate in HbA1c 44–77 compared to 28–39 mmol/mol [24]. The recognized correlations of the abovementioned biomarkers, in addition to their cost-effectiveness and their wide-spread use in everyday clinical practice, renders them attractive candidates for future studies aiming to provide robust data on their relation to AAA expansion rates.

Concurrently, a plethora of less utilized biomarkers correlating to various stages of AAA progression have been studied, posturing as alluring secondary candidates. Firstly, extracellular matrix components and degradation enzymes have been associated with AAA growth rate. The well-defined role of elastin, biglycan, and type III collagen in the structural integrity of the aortic wall provided the basis for studies reporting data on the by-products of these proteins associated with AAA progress and increased sac expansion [18,26,29,56,57]. Inadvertently, extracellular matrix proteinases (MMP-2, MMP-9 [58], cathepsins B, D, L, and S [59]) responsible for ECM cleavage, and proteinases inhibitors (a1-antithrypsin [19], cystatin-B [37], cystatin-C [60]) play a significant role in the aortic wall remodeling occurring in AAA pathogenesis with several studies revealing either positive or inverse correlations with AAA growth rates. An abundance of modulators and mediators expressing the inflammatory and oxidative processes have also been studied with conflicting outcomes [31,32,38,61,62]. Synchronously, studies on promising novel biomarkers requiring genome sequencing analysis have been conducted, with propitious results. Specifically, genomic DNA analysis of genetic polymorphisms showed increased risk of aggressive-growth over slow-growth AAA [36,41,63–65]. Current data on these aforementioned biomarkers are promising, despite the fact that firm conclusions cannot be provided. Interestingly, calprotectin, a protein commonly associated with inflammatory cells (neutrophil granulocytes, monocytes, macrophages), has been related to AAA pathogenesis. These results provide further solid ground for future trials, aiming to assess the relation between the antimicrobial protein and AAA growth rate [66,67]. As the knowledge on AAA pathogenesis increases, novel studies may offer validated markers that could be used for the detection of this high-risk group of patients while pharmaceutical factors may provide a conservative management on AAA presence and expansion.

Limitations

The strength of the current review is limited by a series of factors. Firstly, the retrospective nature of the included studies confines its ability to reach pertinent results. Secondly, vast incoherencies among studies in terms of the types of biomarker assessed, studied population and cohorts, lack of control groups, follow-up intervals, and standardized methodological evaluations (imaging techniques, biomarkers quantification methods) impede the production of robust results, as well as the ability of quantitative analysis of the said results. Finally, most studies were judged as having “Moderate” risk of bias, mainly due to selection bias and inadequate confounder control.
5. Conclusions

Blood circulating biomarkers may offer a valid approach in the future for the detection of AAA expansion. The current literature provides a plethora of data with conflicting results and firm conclusions cannot be provided. In the presence of future robust data, specific serum biomarkers could potentially form the basis of an individualized surveillance strategy of patients presenting with increased AAA growth rates.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10081718/s1, Table S1: PICO model, Table S2: Risk of Bias Assessment (ROBINS-I) for Observational Studies.

Author Contributions: Conceptualization, K.S., G.K.; methodology, P.N., K.D., A.B.; software, A.B.; validation, P.N., A.B.; formal analysis, A.B.; investigation, P.N., K.S., K.D.; data curation, P.N., K.S.; writing—original draft preparation, P.N., K.D.; visualization, G.K.; supervision, G.K.; project administration, K.S., G.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable. No new data were created or analyzed in this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Golledge, J. Abdominal aortic aneurysm: Update on pathogenesis and medical treatments. Nat. Rev. Cardiol. 2018, 16, 225–242. [CrossRef]
2. Kurvers, H.; Veith, F.; Lipsitz, E.; Ohki, T.; Gargiulo, N.; Cayne, N.; Suggs, W.; Timaran, C.; Kwon, G.; Rhee, S. Discontinuous, staccato growth of abdominal aortic aneurysms. J. Am. Coll. Surg. 2004, 199, 709–715. [CrossRef]
3. Olson, S.L.; Wijesinha, M.A.; Panthofer, A.M.; Blackwelder, W.C.; Upchurch, G.R.; Terrin, M.L.; Curci, J.A.; Baxter, B.T.; Matsumura, J.S. Evaluating Growth Patterns of Abdominal Aortic Aneurysm Diameter With Serial Computed Tomography Surveillance. JAMA Surg. 2021. [CrossRef] [PubMed]
4. Spanos, K.; Eckstein, H.-H.; Giannoukas, A.D. Small Abdominal Aortic Aneurysms Are Not All the Same. Angiology 2019, 71, 205–207. [CrossRef]
5. Forsythe, R.O.; Newby, D.E.; Robson, J.M.J. Monitoring the biological activity of abdominal aortic aneurysms beyond Ultrasound. Heart 2016, 102, 817–824. [CrossRef]
6. Jalalzadeh, H.; Indrakusuma, R.; Planken, R.N.; Legemate, D.A.; Koelemay, M.J.W.; Balm, R. Inflammation as a Predictor of Abdominal Aortic Aneurysm Growth and Rupture: A Systematic Review of Imaging Biomarkers. Eur. J. Vasc. Endovasc. Surg. 2016, 56, 333–342. [CrossRef]
7. Spanos, K.; Nana, P.; Kouvelos, G.; Mpatzalexis, K.; Matsagkas, M.; Giannoukas, A.D. Anatomical Differences Between Intact and Ruptured Large Abdominal Aortic Aneurysms. J. Endovasc. Ther. 2020, 27, 117–123. [CrossRef] [PubMed]
8. Wanhainen, A.; Mani, K.; Golledge, J. Surrogate Markers of Abdominal Aortic Aneurysm Progression. Arter. Thromb. Vasc. Biol. 2016, 36, 236–244. [CrossRef]
9. Ahmed, R.; Ghoorah, K.; Kunadian, V. Abdominal aortic aneurysms and risk factors for adverse events. Cardiol. Rev. 2016, 24, 88–93. [CrossRef]
10. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009, 338, b2700. [CrossRef]
63. Duellman, T.; Warren, C.L.; Matsumura, J.; Yang, J. Analysis of multiple genetic polymorphisms in aggressive-growing and slow-growing abdominal aortic aneurysms. *J. Vasc. Surg.* 2014, 60, 613–621. [CrossRef] [PubMed]

64. Zhang, W.; Shang, T.; Huang, C.; Yu, T.; Liu, C.; Qiao, T.; Huang, D.; Liu, Z.; Liu, C. Plasma microRNAs serve as potential biomarkers for abdominal aortic aneurysm. *Clin. Biochem.* 2015, 48, 988–992. [CrossRef] [PubMed]

65. Kin, K.; Miyagawa, S.; Fukushima, S.; Shirakawa, Y.; Torikai, K.; Shimamura, K.; Sawa, Y. Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. *J. Am. Heart Assoc.* 2012, 1, e000745. [CrossRef] [PubMed]

66. Hauzer, W.; Witkiewicz, W.; Gnus, J. Calprotectin and Receptor for Advanced Glycation End Products as a Potential Biomarker in Abdominal Aortic Aneurysm. *J. Clin. Med.* 2020, 9, 927. [CrossRef]

67. Hauzer, W.; Ferenc, S.; Rosińczuk, J.; Gnus, J. The Role of Serum Calprotectin as a New Marker in Abdominal Aortic Aneurysms—A Preliminary Report. *Curr. Pharm. Biotechnol.* 2020, 21. [CrossRef] [PubMed]